RU2018125514A - Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента - Google Patents
Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента Download PDFInfo
- Publication number
- RU2018125514A RU2018125514A RU2018125514A RU2018125514A RU2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A
- Authority
- RU
- Russia
- Prior art keywords
- ahus
- factor
- developing
- use according
- subject
- Prior art date
Links
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title claims 6
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title claims 6
- 230000001419 dependent effect Effects 0.000 title claims 3
- 230000004913 activation Effects 0.000 title 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000024203 complement activation Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010053085 Complement Factor H Proteins 0.000 claims 2
- 102000003712 Complement factor B Human genes 0.000 claims 2
- 108090000056 Complement factor B Proteins 0.000 claims 2
- 102100035432 Complement factor H Human genes 0.000 claims 2
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 claims 2
- 101710101162 Complement factor H-related protein 4 Proteins 0.000 claims 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102000016918 Complement C3 Human genes 0.000 claims 1
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 102100040132 Complement factor H-related protein 1 Human genes 0.000 claims 1
- 101710101151 Complement factor H-related protein 1 Proteins 0.000 claims 1
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims 1
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000002506 anticoagulant protein Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 108010071253 factor H-related protein 1 Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
Claims (12)
1. Применение MASP-2-ингибирующего агента, который ингибирует MASP-2-зависимую активацию комплемента, при изготовлении лекарственного средства для лечения субъекта, страдающего от или подверженного риску развития атипичного гемолитического уремического синдрома (aHUS), где MASP-2-ингибирующий агент представляет собой ингибирующее моноклональное антитело против MASP-2 или его антигенсвязывающий фрагмент, которые специфически связываются с частью SEQ ID NO:6 и селективно ингибируют MASP-2-зависимую активацию комплемента без по существу ингибирования C1q-зависимого пути комплемента.
2. Применение по п.1, где перед введением лекарственного препарата субъект, как определено, проявляет один или более симптомов, выбранных из группы, состоящей из (i) анемии, (ii) тромбоцитопении, (iii) почечной недостаточности и (iv) увеличивающегося креатинина, и лекарственное средство составляют для введения эффективного количества в течение временного периода для улучшения указанного одного или более симптомов.
3. Применение по п.1, где субъект страдает от или подвержен риску развития фактор H-независимого aHUS.
4. Применение по п.1, где субъект страдает от aHUS, связанного с фактором I, фактором B или мембранным кофактором CD46.
5. Применение по п. 1, где для субъекта, подверженного риску развития aHUS, определено наличие генетического маркера, связанного, как известно, с повышенным риском развития атипичного гемолитического уремического синдрома (aHUS).
6. Применение по п.6, где генетический маркер, связанный, как известно, с повышенным риском развития aHUS, в гене, выбранном из группы, включающей фактор H комплемента (CFH), фактор I (CFI), фактор B (CFB), мембранный кофактор CD46, C3, фактор H комплемента-родственный белок 1 (CFHR1), антикоагулянтный белок тромбодулин (THBD), фактор H комплемента-родственный белок 3 (CFHR3) и фактор H комплемента-родственный белок 4 (CFHR4).
7. Применение по п.1, где субъект, подверженный риску развития aHUS, испытал событие, связанное, как известно, с инициированием клинических симптомов aHUS.
8. Применение по п.7, где событие, связанное с инициированием клинических симптомов aHUS, выбирают из группы, состоящей из воздействия препарата, инфекции, злокачественного новообразования, повреждения, трансплантата органа и ткани и беременности.
9. Применение по п.8, где инфекция представляет собой бактериальную инфекцию.
10. Применение по п. 1, где субъект страдает от или подвержен риску развития некишечного aHUS, связанного с инфекцией S. pneumonia.
11. Применение по п.1, где лекарственное средство составляют для подкожного введения.
12. Применение по п. 1, где лекарственное средство составляют для введения субъекту через внутривенный катетер или другим способом катетерной доставки.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473698P | 2011-04-08 | 2011-04-08 | |
| US61/473,698 | 2011-04-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013149792A Division RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021103424A Division RU2852982C2 (ru) | 2011-04-08 | 2021-02-12 | Способы лечения состояний, связанных с masp-2-зависимой активацией комплемента |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018125514A true RU2018125514A (ru) | 2019-03-12 |
| RU2018125514A3 RU2018125514A3 (ru) | 2019-10-30 |
| RU2743409C2 RU2743409C2 (ru) | 2021-02-18 |
Family
ID=46966283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013149792A RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
| RU2018125514A RU2743409C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013149792A RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8951522B2 (ru) |
| EP (3) | EP3287142B1 (ru) |
| JP (4) | JP5937197B2 (ru) |
| KR (6) | KR20210021101A (ru) |
| CN (3) | CN107638565B (ru) |
| AU (1) | AU2012239889B2 (ru) |
| BR (1) | BR112013025917A2 (ru) |
| CA (4) | CA2977009C (ru) |
| CL (1) | CL2013002874A1 (ru) |
| DK (2) | DK2694108T3 (ru) |
| ES (2) | ES2683307T3 (ru) |
| IL (3) | IL228758B (ru) |
| MX (3) | MX339002B (ru) |
| NZ (5) | NZ731596A (ru) |
| PL (1) | PL3287142T3 (ru) |
| RU (2) | RU2662563C2 (ru) |
| WO (1) | WO2012139081A2 (ru) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0688182B2 (ja) | 1986-09-08 | 1994-11-09 | バブコツク日立株式会社 | スタツド着脱装置 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP3287142B1 (en) | 2011-04-08 | 2021-08-04 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| SG10201703249PA (en) * | 2011-12-21 | 2017-05-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| PL2833907T3 (pl) * | 2012-04-06 | 2018-08-31 | Omeros Corporation | Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii |
| JP6445972B2 (ja) * | 2012-06-18 | 2018-12-26 | オメロス コーポレーション | 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法 |
| JP6538561B2 (ja) | 2012-10-25 | 2019-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| AU2014229020B2 (en) * | 2013-03-15 | 2017-09-28 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN105683219B (zh) | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化有关的病况的方法 |
| WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| ES2938359T3 (es) | 2015-04-06 | 2023-04-10 | Bioverativ Usa Inc | Anticuerpos humanizados anti-C1s y métodos de uso de los mismos |
| CA3004753C (en) * | 2015-11-09 | 2023-02-28 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| ES2941640T3 (es) | 2015-12-16 | 2023-05-24 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento |
| AU2016375183B2 (en) * | 2015-12-23 | 2021-01-21 | eleva GmbH | Polypeptides for inhibiting complement activation |
| KR102564616B1 (ko) * | 2016-01-05 | 2023-08-08 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| IL262021B2 (en) * | 2016-03-31 | 2024-01-01 | Omeros Corp | Masp-2 inhibitory agents for use in inhibiting angiogenesis |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| FI3525583T3 (fi) | 2016-10-12 | 2025-10-31 | Bioverativ Usa Inc | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
| WO2018124132A1 (ja) * | 2016-12-26 | 2018-07-05 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
| WO2018164186A1 (ja) * | 2017-03-09 | 2018-09-13 | 協和発酵キリン株式会社 | Ｍａｓｐ２の発現を抑制する核酸 |
| CN116898870A (zh) * | 2017-07-28 | 2023-10-20 | 雷莫内克斯生物制药有限公司 | 用于预防或治疗肝癌的药物组合物 |
| US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| SG11202005181RA (en) | 2017-12-04 | 2020-07-29 | Ra Pharmaceuticals Inc | Modulators of complement activity |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| SG11202010925UA (en) * | 2018-05-29 | 2020-12-30 | Omeros Corp | Masp-2 inhibitors and methods of use |
| RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
| CN111655849B (zh) | 2018-08-21 | 2024-05-10 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| EP3628735A1 (en) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| KR20210092761A (ko) * | 2018-11-15 | 2021-07-26 | 아이오니스 파마수티컬즈, 인코포레이티드 | Irf5 발현 조절인자 |
| WO2020132844A1 (zh) * | 2018-12-25 | 2020-07-02 | 中国医学科学院基础医学研究所 | 炎性相关疾病防治的小rna药物及其组合 |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2020184700A1 (ja) * | 2019-03-14 | 2020-09-17 | レナセラピューティクス株式会社 | Ｉｈｈ発現を調節するための核酸複合体 |
| CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
| WO2020219822A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| CN113614230B (zh) * | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
| JP7227401B2 (ja) | 2019-11-27 | 2023-02-21 | 京セラ株式会社 | 通信制御方法及びユーザ装置 |
| AU2020396565C1 (en) | 2019-12-04 | 2025-05-15 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| KR20220110530A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| WO2021113698A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| KR20220110529A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| WO2021168148A1 (en) * | 2020-02-19 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| WO2021231720A1 (en) * | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113674860B (zh) * | 2020-05-15 | 2024-05-17 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、系统及其应用 |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN114634575B (zh) * | 2020-12-16 | 2025-04-11 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| JP2024518724A (ja) * | 2021-04-25 | 2024-05-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途 |
| GEAP202516705A (en) | 2021-12-10 | 2025-04-10 | Omeros Corp | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| MA71613A (fr) * | 2022-07-25 | 2025-05-30 | Amgen Inc. | Constructions d'arni et méthodes d'inhibition de l'expression de fam13a |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN119978131B (zh) * | 2025-04-15 | 2025-06-27 | 北京赛斯维德生物科技有限公司 | 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| WO2000035483A1 (en) | 1998-12-15 | 2000-06-22 | The Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| EP1797869A3 (en) | 1999-07-21 | 2008-07-23 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| EP1238066A2 (en) | 1999-12-02 | 2002-09-11 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| EP1303591B1 (en) | 2000-07-13 | 2009-06-24 | Helion Biotech ApS | Masp-2, a complement-fixing enzyme, and uses for it |
| EP1416962A4 (en) | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | METHOD FOR IMPROVING THE COGNITIVE FUNCTION |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION |
| WO2003081206A2 (en) | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| JP2006504661A (ja) | 2002-07-30 | 2006-02-09 | オメロス コーポレイション | 眼科学的洗浄溶液および眼科学的洗浄方法 |
| ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
| AU2003283217A1 (en) | 2002-12-03 | 2004-06-23 | Aarhus Amt | Method for determing predisposition to manifestation of immune system related diseases |
| JP2006518749A (ja) | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
| AU2004221982B2 (en) * | 2003-03-17 | 2011-10-13 | Km Biologics Co., Ltd. | Construct comprising recognition domain of antibody against von Willebrand factor-specific cleaving enzyme |
| PT2374819T (pt) | 2003-05-12 | 2017-07-04 | Helion Biotech Aps | Anticorpos para masp-2 |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| CA2847677C (en) * | 2004-06-10 | 2018-05-01 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20070015703A1 (en) * | 2005-06-17 | 2007-01-18 | Denisa Wagner | ADAMTS13-containing compositions having thrombolytic activity |
| EP1987354B1 (en) | 2006-01-27 | 2010-11-03 | Rappaport Family Institute for Research in the Medical Sciences | Methods for determining blood coagulation |
| KR101513308B1 (ko) | 2006-03-08 | 2015-04-28 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| EP2894166A1 (en) * | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| JP2012533288A (ja) | 2009-07-17 | 2012-12-27 | リグショスピタレト | 補体活性化の阻害剤 |
| KR101759895B1 (ko) | 2009-10-16 | 2017-07-20 | 오메로스 코포레이션 | Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법 |
| EA201290286A1 (ru) * | 2009-11-05 | 2013-01-30 | Алексион Кембридж Корпорейшн | Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза |
| SG183541A1 (en) | 2010-03-01 | 2012-10-30 | Alexion Pharma Inc | Methods and compositions for treating degos' disease |
| EP3287142B1 (en) | 2011-04-08 | 2021-08-04 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| RS60541B1 (sr) | 2011-05-04 | 2020-08-31 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| JP6445972B2 (ja) | 2012-06-18 | 2018-12-26 | オメロス コーポレーション | 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法 |
| CN105683219B (zh) | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化有关的病况的方法 |
| CA3004753C (en) | 2015-11-09 | 2023-02-28 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| IL262021B2 (en) * | 2016-03-31 | 2024-01-01 | Omeros Corp | Masp-2 inhibitory agents for use in inhibiting angiogenesis |
| JPWO2018070521A1 (ja) * | 2016-10-14 | 2019-08-15 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Ceased
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active Active
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/en active
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko not_active Ceased
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Ceased
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
- 2012-04-06 CA CA3237802A patent/CA3237802A1/en active Pending
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 CA CA3076975A patent/CA3076975C/en active Active
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active Active
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active Active
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en not_active Ceased
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 MX MX2018005314A patent/MX381987B/es unknown
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018125514A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| Joannes-Boyau et al. | High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial | |
| Jodele et al. | Tackling COVID‐19 infection through complement‐targeted immunotherapy | |
| JP2014530226A5 (ru) | ||
| Cocanour et al. | Management and novel adjuncts of necrotizing soft tissue infections | |
| JP2013533858A5 (ru) | ||
| Kim et al. | Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation | |
| EA201201660A1 (ru) | Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов | |
| JP2020504110A5 (ru) | ||
| Li et al. | Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1α, VEGF and TGF-β1 | |
| Holman et al. | Device related infections: are we making progress? | |
| Christensen et al. | The role of neutrophils and G‐CSF in DNFB‐induced contact hypersensitivity in mice | |
| He et al. | Effects of continuous renal replacement therapy on intestinal mucosal barrier function during extracorporeal membrane oxygenation in a porcine model | |
| Alvarado-Tapias et al. | Alcohol-associated liver disease: Natural history, management and novel targeted therapies | |
| JP2010539974A5 (ru) | ||
| Liu et al. | Protective effect of endothelial progenitor cell-derived exosomal microRNA-382-3p on sepsis-induced organ damage and immune suppression in mice | |
| Johnson et al. | Peritoneal dialysis | |
| van Ruler et al. | Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights | |
| Yang et al. | Infection and Immunodeficiency in Patients With Chronic Kidney Disease: Current Evidence and Potential Preventive Strategies of Chinese Medicine | |
| WO2012113343A1 (zh) | Il-17抑制剂在制备治疗和/或预防肺损伤的药物中的用途 | |
| JP2020534280A5 (ru) | ||
| Kim et al. | Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus | |
| JP6860480B2 (ja) | マクロファージ炎症性タンパク質−１β抑制剤の使用方法 | |
| CN113413464A (zh) | 抗pd-l1抗体在急性呼吸窘迫综合征治疗药物中的应用 | |
| Kim et al. | Transplantation in highly HLA-sensitized patients: challenges and solutions |